Hepatology research : the official journal of the Japan Society of Hepatology · 2026
Low Alpha-Fetoprotein in Non-Viral Early-Stage Hepatocellular Carcinoma: Complementary Des-Gamma-Carboxyprothrombin.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ikeda Yuji, Sato Shunsuke, Om Rihwa, Yamaguchi Masahiro, Nago Hiroki, Terai Yuichiro, Kita Yuji, Sato Sho, Murata Ayato, Shimada Yuji, Hamamura Keisuke, Oyaizu Tatsuki, Genda Takuya
Аннотация
BACKGROUND AND AIM: Alpha-fetoprotein (AFP) is widely used in hepatocellular carcinoma (HCC) surveillance, but its performance may vary with etiology and tumor stage. We assessed etiology-specific AFP and des-gamma-carboxyprothrombin (DCP) positivity at HCC diagnosis, focusing on early-stage disease.
METHODS: We retrospectively enrolled consecutive adults with newly diagnosed, treatment-naïve HCC at two tertiary centers in Japan (2007-2023). AFP (cutoff ≥ 10 ng/mL) and DCP (≥ 40 mAU/mL) at diagnosis were analyzed overall and by etiology (Hepatitis B virus (HBV), Hepatitis C virus (HCV), sustained virological response [SVR], and non-B/non-C [NBNC]). Early stage was defined as Barcelona Clinic Liver Cancer (BCLC) 0/A and Union for International Cancer Control tumor-node-metastasis (UICC) T1a.
RESULTS: Among 1396 patients, 760 (54.4%) had BCLC 0/A and 278 (19.9%) had T1a tumors. AFP positivity differed by etiology in BCLC 0/A disease (HBV 50.0%, HCV 64.6%, SVR-related 39.0%, NBNC 39.7%; p < 0.001), and in T1a tumors (48.1%, 60.3%, 39.0%, and 34.5%, respectively; p = 0.002). DCP (n = 1364) positivity in BCLC 0/A showed less variability (40.6%, 47.8%, 40.8%, and 58.4%, respectively; p = 0.005). Either-marker positivity in BCLC 0/A increased (64.1%, 80.0%, 59.2%, and 70.6%, respectively); the incremental yield from DCP alone among AFP-negative cases was 21.1% in SVR-related and 30.5% in NBNC early-stage HCC.
CONCLUSION: AFP positivity at diagnosis was substantially lower in early-stage SVR-related and NBNC HCC than in HCV-related HCC. Adding DCP provides complementary detection, supporting an etiology-aware dual-marker strategy at diagnosis.
METHODS: We retrospectively enrolled consecutive adults with newly diagnosed, treatment-naïve HCC at two tertiary centers in Japan (2007-2023). AFP (cutoff ≥ 10 ng/mL) and DCP (≥ 40 mAU/mL) at diagnosis were analyzed overall and by etiology (Hepatitis B virus (HBV), Hepatitis C virus (HCV), sustained virological response [SVR], and non-B/non-C [NBNC]). Early stage was defined as Barcelona Clinic Liver Cancer (BCLC) 0/A and Union for International Cancer Control tumor-node-metastasis (UICC) T1a.
RESULTS: Among 1396 patients, 760 (54.4%) had BCLC 0/A and 278 (19.9%) had T1a tumors. AFP positivity differed by etiology in BCLC 0/A disease (HBV 50.0%, HCV 64.6%, SVR-related 39.0%, NBNC 39.7%; p < 0.001), and in T1a tumors (48.1%, 60.3%, 39.0%, and 34.5%, respectively; p = 0.002). DCP (n = 1364) positivity in BCLC 0/A showed less variability (40.6%, 47.8%, 40.8%, and 58.4%, respectively; p = 0.005). Either-marker positivity in BCLC 0/A increased (64.1%, 80.0%, 59.2%, and 70.6%, respectively); the incremental yield from DCP alone among AFP-negative cases was 21.1% in SVR-related and 30.5% in NBNC early-stage HCC.
CONCLUSION: AFP positivity at diagnosis was substantially lower in early-stage SVR-related and NBNC HCC than in HCV-related HCC. Adding DCP provides complementary detection, supporting an etiology-aware dual-marker strategy at diagnosis.